Suicide, Attempted Clinical Trial
Official title:
Double-Blind Randomized Controlled Trial of Acute-Course of Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents
This project aims to examine the efficacy of ketamine, a rapidly acting medication shown to decrease suicidality in adults in as short as hours or days, as opposed to weeks. The study design is a double-blind, randomized, active-control trial of adolescents (ages 13-18 years) with recent suicidal behaviors (suicide attempt or increased suicidal ideation). All participants must be receiving standard of care treatment which may range broadly from both outpatient and inpatient programs which include clinically indicated psychosocial and/or psychopharmacological treatments. Ketamine/midazolam treatment will occur twice weekly during the first two weeks of the study, followed by weekly assessments through week 12.
Status | Recruiting |
Enrollment | 264 |
Est. completion date | November 1, 2026 |
Est. primary completion date | May 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 13 Years to 18 Years |
Eligibility | Inclusion Criteria Study participants must: 1. Be adolescents (aged 13-18 years); 2. Have had a recent suicidal event (suicide attempt or significant suicidal ideation with a plan or intent warranting emergency evaluation or inpatient hospitalization within the past 90 days); 3. Receiving standard of care treatment that includes clinically indicated psychosocial and/or psychopharmacological treatment; 4. Have a current primary diagnosis of a depressive disorder based on the MINI-KID (other psychiatric disorders are acceptable, but must not be primary); 5. Both participants and their designated caregiver must be able to complete assessments in English, as the rating scales vital to study efficacy and safety evaluations have not been validated in Spanish. (NOTE: Most potential participants ages 13 to 18 years old, as well as most of their parents, have a good working knowledge of English); 6. Use effective method of contraception during and for 90 days following the end of treatment for female and male participants. Recommended methods of birth control are namely, consistent use of an approved hormonal birth control (pill/patches, rings), an intrauterine device (IUD), contraceptive injection, double barrier methods, sexual abstinence, or sterilization; Exclusion Criteria Study participants must not: 1. Have a psychotic disorder, such as lifetime schizophrenia, or a pervasive or intellectual developmental disorder requiring substantial or very substantial support; 2. Have current mania, hypomania, mixed episode, or obsessive-compulsive disorder; 3. Have a primary diagnosis other than a depressive disorder; 4. Have moderate to severe alcohol or substance use disorder within the past six months (based on MINI-KID); If there is a positive urine drug screen at screening, the urine drug screen will be repeated at each infusion visit. Positive urine drug screen will be reviewed by study physician and infusion will proceed as long as no safety risk was identified; 5. If female, be pregnant, lactating, or nursing; Women of childbearing potential must have a negative urine pregnancy test prior to all infusions; 6. Have unstable medical conditions (stable for less than 3 months) or with clinically significant laboratory values or an electrocardiogram (ECG) that would pose significant risk; 7. Be at serious suicidal risk that cannot be managed in the outpatient setting; 8. Have prior treatment for depression with or contraindications to ketamine, esketamine, or, midazolam; 9. Treatment with medications that may alter pharmacokinetics of ketamine, including moderate-to-strong inhibitors or inducers of CYP3A4 and CYP2B6, is exclusionary. Regarding pharmacodynamic interactions, medications that may increase heart rate or blood pressure such as the ADHD stimulant medications will be permitted with last dose at least 24 hours prior to infusion. All concomitant medications will be evaluated by the study physician to determine if the type and dose of concomitant medication requires discontinuation and will be excluded if the concomitant medication could substantially increase the risk of study infusion. A complete list of medications that are Not Allowed is available in Appendix D of the protocol. The study team will not ask the participant to discontinue any treatment (except for not taking ADHD medications for 24 hours before study treatment) just for the sake of taking part in this study; 10. Weigh >120 kilograms at baseline. If participants are enrolled but exceed 120 kilograms at any time during the treatment period, they will be removed from the treatment portion of the study. |
Country | Name | City | State |
---|---|---|---|
United States | UT Southwestern Medical Center | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas Southwestern Medical Center | National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary outcome for the study is "suicidal events". Suicidal event is defined as a suicide attempt, or emergency department visit or inpatient hospitalization due to suicidality. | Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C) will be used to identify suicidal events. The CHRT-C consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. | 12 weeks | |
Secondary | Death/Suicide Implicit Association Test (IAT) | The IAT is a performance-based measure of cognition that has demonstrated good reliability and sensitivity to change. The IAT measures associations based on response latency where the response time is compared across categorization tasks. | 2 weeks | |
Secondary | Depression symptoms as measured by CHRT-SR a self report measure | (specify for each) Concise Health Risk Tracking Self-Report (CHRT-SR) consists of 14 questions with responses ranging from 0 (strongly disagree) to 4 (strongly agree). 1) the Propensity subscale, which consists of 9 questions and 4 factors (pessimism, helplessness, social support, and despair) and a score range of 0-36; and the Suicidal Thoughts subscale, which consists of 3 questions and a score range of 0-9 (which will serve as the primary suicidal behavior outcome in this study); and 3) Impulsivity, which consists of 2 questions and a score range of 0-6. A total score is also calculated, ranging from 0 to 56. | 2 weeks | |
Secondary | Number of participants with suicidal events/behaviors as measured by CHRT-C a self report measure | Concise Health Risk Tracking Clinician-Rated Behavior Module (CHRT-C). consists of nine clinician-rated yes/no items about specific behaviors (i.e., suicidal ideation, suicidal attempt, preparatory acts, non-suicidal self-injury (NSSI), other injuries, etc.). At the initial administration, this instrument captures lifetime information; at subsequent administrations, it will capture information since the last visit. a yes on any of the 9 questions indicates presence of suicidal event/behaviors (ideation, attempt, preparatory acts, non suicidal self injury, other injury). | 2 week | |
Secondary | Depression symptoms as measured by the Inventory of Depressive Symptomatology (IDS), self-report measure | The Inventory of Depressive Symptomatology (IDS) Self Report is a depressive symptom severity measure that rates all nine criterion symptoms of MDD, and includes an irritability item for adolescents. The self report (IDS-SR) will be completed at each visit. | 2 weeks | |
Secondary | Depression symptoms as measured by the Inventory of Depressive Symptomatology (IDS), Parent self report measure | The Inventory of Depressive Symptomatology (IDS) Parent Report is a depressive symptom severity measure that rates all nine criterion symptoms of MDD, and includes an irritability item for adolescents. The parent self report (IDS-SR Parent) will be completed at each visit. | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03185026 -
Psychoeducation for Suicidal Behavior
|
N/A | |
Recruiting |
NCT05609487 -
Evaluation of the Safety Plan to Prevent Suicidal Reiteration
|
N/A | |
Recruiting |
NCT06322199 -
Differences Between Suicide Attempters and Suicide Ideators. Influence of the Brief Therapy Attempted Suicide Short Intervention Program (ASSIP) on Neuropsychological Correlates and Psychological Process Factors - Project 3
|
||
Completed |
NCT03134885 -
Evaluation of a Regional Post-discharge Monitoring System for Suicide Attempters
|
||
Completed |
NCT01535482 -
Cognitive Therapy for Suicidal Older Men
|
N/A | |
Completed |
NCT01118208 -
Blister Packaging Medication to Increase Treatment Adherence and Clinical Response
|
N/A | |
Completed |
NCT01360736 -
A Brief Intervention to Reduce Suicide Risk in Military Service Members and Veterans - Study 2 (SAFEMIL)
|
N/A | |
Completed |
NCT05580757 -
Pharmacists as Gate Keepers in Suicide Prevention: Needs of Pharmacists
|
||
Not yet recruiting |
NCT05427734 -
Treating Drivers of Suicide Using Jaspr Health
|
N/A | |
Recruiting |
NCT06406972 -
Brief Admission by Self-referral for Individuals With Self-harm: Effects on Compulsory Care
|
||
Recruiting |
NCT05537376 -
A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness
|
N/A | |
Completed |
NCT03227991 -
Safety Planning Intervention to Reduce Short Term Risk
|
N/A | |
Recruiting |
NCT04962373 -
Brief Admission for Adolescents Who Self-harm
|
||
Completed |
NCT02985047 -
Brief Admission Skane: Replacing General Admission for Individuals With Self-harm and Acute Risk of Suicide
|
N/A | |
Enrolling by invitation |
NCT06060535 -
Implementation of Suicide Risk Models in Health Systems
|
N/A | |
Recruiting |
NCT04994873 -
Skills to Enhance Positivity in Suicidal Youth
|
N/A | |
Completed |
NCT01176929 -
Randomized Controlled and Prospective Trial of a Cohort of People Who Made a Suicide Attempt
|
N/A | |
Completed |
NCT00558805 -
Family Intervention for Suicidal Youth: Emergency Care
|
Phase 2 | |
Recruiting |
NCT05390918 -
Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior
|
N/A | |
Recruiting |
NCT04746261 -
A Randomized Clinical Study of "Attempted Suicide Short Intervention Program" in Swedish Healthcare - ASSIP
|
N/A |